HOOK 241220 2.50C (HOOK241220C2500) Stock Options, News & Quotes

0.20
+0.02+11.11%

15min DelayClose Nov 27 16:00 ET

0.20High0.18Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

102270433

Nov 25 07:28

$HOOKIPA Pharma (HOOK.US)$
With Gilead Science holding 15% share, it is worthwhile to hold long...

Trytosaveabit

Nov 11 12:09

Watching!

$HOOKIPA Pharma (HOOK.US)$ Watching for news out of the presentation at SITC 2024 from Saturday!

Jaguar8

Oct 31 08:21

NEWS

$HOOKIPA Pharma (HOOK.US)$
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
HOOKIPA Pharma (NASDAQ: HOOK) announced that updated Phase 2 data for eseba-vec (HB200) plus pembrolizumab in first-line recurrent/metastatic HPV16-positive head and neck cancer will be presented at SITC 2024. The presentation will be delivered as a late-breaking poster by Dr. Alan Ho, Chief of Head and Neck Oncology Service at Memorial Sloan Cancer Cent...

Trytosaveabit

Oct 30 06:32

Update

$HOOKIPA Pharma (HOOK.US)$ Reuters· 2 mins ago
HOOKIPA Pharma Doses First Patients With Eseba-Vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer

Trytosaveabit

Sep 24 06:48

Watching! Look at date/time!

$HOOKIPA Pharma (HOOK.US)$ HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
16 MINUTES AGO, 7:30 AM EDT
VIA GLOBENEWSWIRE
NEW YORK and VIENNA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced that the Company will present preclinical data related...